BRD5631

®

MedChemExpress

BIOLOGICAL ACTIVITY		
Description	BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production ^[1] .	
IC ₅₀ & Target	Autophagy ^[1]	
In Vitro	 BRD5631 (10 μM, 48 hours) leads to increased levels of LC3-II in HeLa cells. BRD5631 stimulates formation of new autophagosomes, which is consistent with its ability to increase numbers of autolysosomes in the mCherry-GFP-LC3 assay^[1]. BRD5631 does not enhance autophagy by directly inhibiting mTOR or the mTOR signaling pathway. BRD5631 suppressed IL-1β secretion in an autophagy-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1] 	
	Cell Line:	HeLa cells.
	Concentration:	10 μM.
	Incubation Time:	48 hours.
	Result:	Led to increased levels of LC3-II.

REFERENCES

[1]. Kuo SY, et al. Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4281-7.

Product Data Sheet

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA